Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
EIK-1001 by Eikon Therapeutics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
EIK-1001 is under clinical development by Eikon Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...